How certain bacteria can enhance cancer treatment effectiveness
Defining mechanisms of how immune checkpoint inhibitor-associated bacteria modulate tumor immunity in cancer
This study is looking at how certain good bacteria in your gut might help make cancer treatments work better for melanoma patients by boosting the immune system, especially the cells that fight tumors, and it hopes to find new ways to improve treatment for those who haven't had success with current options.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-11131468 on NIH RePORTER |
What this research studies
This research investigates the role of specific bacteria in the gut microbiome that may improve the effectiveness of immune checkpoint inhibitors (ICIs) in cancer treatment, particularly for melanoma patients. The study aims to understand the mechanisms by which these bacteria enhance anti-tumor immunity, focusing on how they influence CD8+ T cells, which are crucial for fighting cancer. By exploring the interaction between dietary components and gut bacteria, the research seeks to identify new strategies to boost the immune response against tumors, potentially leading to better outcomes for patients resistant to current therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are melanoma patients who are currently undergoing or considering immune checkpoint inhibitor therapy.
Not a fit: Patients with cancers that do not respond to immune checkpoint inhibitors or those who are not eligible for such therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved cancer treatments that enhance the effectiveness of existing therapies for patients with melanoma and potentially other cancers.
How similar studies have performed: Previous research has shown promising results in enhancing cancer treatment through microbiome interactions, suggesting that this approach could lead to significant advancements in cancer therapy.
Where this research is happening
Pittsburgh, United States
- University of Pittsburgh at Pittsburgh — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Meisel, Marlies — University of Pittsburgh at Pittsburgh
- Study coordinator: Meisel, Marlies
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.